Turtle Creek Wealth Advisors LLC Purchases 7,136 Shares of Becton, Dickinson and Company $BDX

Turtle Creek Wealth Advisors LLC raised its position in Becton, Dickinson and Company (NYSE:BDX) by 248.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 10,012 shares of the medical instruments supplier’s stock after purchasing an additional 7,136 shares during the period. Turtle Creek Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $1,792,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. Fort Washington Investment Advisors Inc. OH increased its stake in shares of Becton, Dickinson and Company by 0.5% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,112,958 shares of the medical instruments supplier’s stock worth $199,672,000 after buying an additional 5,109 shares during the last quarter. First Pacific Financial boosted its stake in Becton, Dickinson and Company by 14.8% during the 3rd quarter. First Pacific Financial now owns 4,736 shares of the medical instruments supplier’s stock valued at $876,000 after acquiring an additional 612 shares during the last quarter. Fortitude Family Office LLC boosted its stake in Becton, Dickinson and Company by 144.2% during the 3rd quarter. Fortitude Family Office LLC now owns 210 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 124 shares during the last quarter. First Citizens Bank & Trust Co. grew its holdings in Becton, Dickinson and Company by 120.8% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 9,148 shares of the medical instruments supplier’s stock worth $1,637,000 after acquiring an additional 5,005 shares in the last quarter. Finally, Focus Financial Network Inc. increased its position in shares of Becton, Dickinson and Company by 31.1% in the 3rd quarter. Focus Financial Network Inc. now owns 3,391 shares of the medical instruments supplier’s stock worth $607,000 after purchasing an additional 805 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This represents a 0.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,906 shares of company stock valued at $1,265,855 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX traded up $3.58 on Thursday, reaching $192.47. The company had a trading volume of 757,070 shares, compared to its average volume of 2,469,516. The company has a fifty day moving average of $183.41 and a 200-day moving average of $163.23. The company has a market capitalization of $53.03 billion, a P/E ratio of 57.97, a PEG ratio of 12.63 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.67.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Analyst Ratings Changes

BDX has been the topic of several research analyst reports. Barclays assumed coverage on shares of Becton, Dickinson and Company in a research report on Wednesday, October 7th. They set an “underweight” rating and a $165.00 price target on the stock. Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Bank of America boosted their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Finally, Weiss Ratings upgraded shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.